Literature DB >> 21767614

Vascular endothelial growth factor C acts as a neurotrophic factor for dopamine neurons in vitro and in vivo.

M Piltonen1, A Planken, O Leskelä, T T Myöhänen, A-L Hänninen, P Auvinen, K Alitalo, J-O Andressoo, M Saarma, P T Männistö.   

Abstract

Neurotrophic factors regulate the development and maintenance of the nervous system and protect and repair dopaminergic neurons in animal models of Parkinson's disease (PD). Vascular endothelial growth factors A (VEGF-A) and B have also neurotrophic effects on various types of neurons, including dopaminergic neurons. We examined the ability of the key lymphangiogenic factor VEGF-C to protect dopaminergic cells in vitro and in vivo. The study was initiated by a finding from microarray profiling of Neuro2A-20 cells which revealed up-regulation of VEGF-C by glial cell-line-derived neurotrophic factor (GDNF). Next, we observed that VEGF-C can rescue embryonic dopaminergic neurons and activate the mitogen-activated protein kinase/extracellular signal regulated kinase (MAPK/ERK) pathway in vivo. VEGF receptors 1-2 and co-receptors, neuropilins 1-2, were expressed both in mouse embryonic cultures and adult midbrains. In vivo, VEGF-C had a robust functional effect in the rat unilateral 6-hydroxydopamine (6-OHDA) model of PD and there was a small additive effect on the survival of tyrosine hydroxylase (TH)-positive cells with GDNF. The neuroprotective effect of VEGF-C is most likely due to a combination of direct and indirect neurotrophic effects because, VEGF-C, unlike GDNF, induced also angiogenesis in the striatum following 6-OHDA insult as it did in human umbilical vein endothelial cells (HUVEC). However, we detected activation of astroglia and microglia as well as blood-brain barrier disruption after intracerebral delivery of VEGF-C, raising a concern of its safe usage as a therapeutic molecule. Our results provide evidence of VEGF-C as a neurotrophic factor that influences the dopaminergic system through multiple mechanisms.
Copyright © 2011 IBRO. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21767614     DOI: 10.1016/j.neuroscience.2011.06.084

Source DB:  PubMed          Journal:  Neuroscience        ISSN: 0306-4522            Impact factor:   3.590


  18 in total

Review 1.  Gene and protein therapies utilizing VEGF for ALS.

Authors:  Orion P Keifer; Deirdre M O'Connor; Nicholas M Boulis
Journal:  Pharmacol Ther       Date:  2013-10-29       Impact factor: 12.310

2.  Differential expression of vascular endothelial growth factor isoforms and receptor subtypes in the infarcted heart.

Authors:  Tieqiang Zhao; Wenyuan Zhao; Yuanjian Chen; Li Liu; Robert A Ahokas; Yao Sun
Journal:  Int J Cardiol       Date:  2012-07-19       Impact factor: 4.164

3.  Association of VEGF gene polymorphisms with sporadic Parkinson's disease in Chinese Han population.

Authors:  Yubin Wu; Yingying Zhang; Xun Han; Xiaoyuan Li; Li Xue; Anmu Xie
Journal:  Neurol Sci       Date:  2016-08-01       Impact factor: 3.307

4.  Expression of vascular endothelial growth factor-C (VEGF-C) and its receptor (VEGFR-3) in the glial reaction elicited by human mesenchymal stem cell engraftment in the normal rat brain.

Authors:  Yoo-Jin Shin; Tae-Ryong Riew; Joo-Hee Park; Ha-Jin Pak; Mun-Yong Lee
Journal:  J Histochem Cytochem       Date:  2014-12-03       Impact factor: 2.479

5.  Secreted ectodomain of sialic acid-binding Ig-like lectin-9 and monocyte chemoattractant protein-1 promote recovery after rat spinal cord injury by altering macrophage polarity.

Authors:  Kohki Matsubara; Yoshihiro Matsushita; Kiyoshi Sakai; Fumiya Kano; Megumi Kondo; Mariko Noda; Noboru Hashimoto; Shiro Imagama; Naoki Ishiguro; Akio Suzumura; Minoru Ueda; Koichi Furukawa; Akihito Yamamoto
Journal:  J Neurosci       Date:  2015-02-11       Impact factor: 6.167

Review 6.  Chinese Herbal Medicine Adjusting Brain Microenvironment via Mediating Central Nervous System Lymphatic Drainage in Alzheimer's Disease.

Authors:  Xi-Bin Zhou; Yu-Xing Zhang; Chun-Xiang Zhou; Jun-Jie Ma
Journal:  Chin J Integr Med       Date:  2021-11-03       Impact factor: 1.978

Review 7.  Current disease modifying approaches to treat Parkinson's disease.

Authors:  Dan Lindholm; Johanna Mäkelä; Valentina Di Liberto; Giuseppa Mudò; Natale Belluardo; Ove Eriksson; Mart Saarma
Journal:  Cell Mol Life Sci       Date:  2015-11-30       Impact factor: 9.261

8.  Age-associated decrease in GDNF and its cognate receptor GFRα-1 protein expression in human skin.

Authors:  Mohamed A Adly; Hanan A Assaf; Mahmoud Rezk Abdelwahed Hussein
Journal:  Int J Exp Pathol       Date:  2016-06-27       Impact factor: 1.925

9.  Elevated Expression of VEGF-C and Its Receptors, VEGFR-2 and VEGFR-3, in Patients with Mesial Temporal Lobe Epilepsy.

Authors:  Fei-Ji Sun; Yu-Jia Wei; Song Li; Wei Guo; Xin Chen; Shi-Yong Liu; Jiao-Jiang He; Qing Yin; Hui Yang; Chun-Qing Zhang
Journal:  J Mol Neurosci       Date:  2016-01-21       Impact factor: 3.444

10.  Chronic VEGFR-3 signaling preserves dendritic arborization and sensitization under stress.

Authors:  Adri Chakraborty; Raghavendra Upadhya; Timaj A Usman; Ashok K Shetty; Joseph M Rutkowski
Journal:  Brain Behav Immun       Date:  2021-08-11       Impact factor: 7.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.